Cartherics CEO to attend London Life Sciences Week as ovarian cancer program advances

Cartherics says CEO Dr. Ian Nisbet will attend London Life Sciences Week from Nov. 15-20 as the Melbourne biotech looks to build partnerships and investor interest around its lead cell therapy CTH-401. The company says the program is moving toward a first-in-human ovarian cancer trial in early 2027, pending regulatory clearance.

Why it matters: - Cartherics is trying to speed its lead program, CTH-401, toward a first-in-human ovarian cancer trial in early 2027, subject to regulatory clearance. - Ovarian cancer remains one of the deadliest cancers affecting women, with most patients diagnosed at an advanced stage and only around one in three surviving beyond five years. - The company is also positioning its broader iPSC platform for more off-the-shelf therapies in solid tumors and endometriosis.

What happened: - Cartherics said CEO Dr. Ian Nisbet will attend London Life Sciences Week from Nov. 15-20, 2026. - The Melbourne-based biotech plans to use the event to promote the company and meet potential partners, collaborators and investors. - Nisbet said the event is becoming a major date in the biotechnology investment and partnering calendar.

The details: - CTH-401 is an off-the-shelf, stem cell-derived CAR-NK cell therapy designed to target TAG-72, a protein expressed on most ovarian cancers. - The therapy is made in advance from a single master cell bank, with the goal of manufacturing at scale rather than custom-making treatment for each patient. - Cartherics has invested in its own clinical manufacturing facility in Melbourne, giving the company direct control over CTH-401 production for clinical trials. - The in-house manufacturing setup is meant to reduce a common source of delay in cell therapy development and support consistent supply as the program moves toward the clinic. - Cartherics says the facility also supports efficient development of follow-on products. - The company is seeking partnerships to advance CTH-401 and to develop its broader iPSC platform. - The platform is designed to generate additional off-the-shelf cell therapies across solid tumors and in endometriosis.

Between the lines: - Cartherics is using the London event to de-risk the next phase of development by building relationships that can support clinical progress and future financing. - Control over manufacturing can be a competitive advantage in cell therapy, where production bottlenecks often slow trials and commercialization. - The pitch blends a near-term clinical milestone with a broader platform story, which may help the company attract both program-specific and platform-level interest.

What's next: - Cartherics expects CTH-401 to move toward a first-in-human ovarian cancer trial in early 2027 if regulators clear the program. - Dr. Nisbet is expected to continue meetings with potential partners and investors during London Life Sciences Week. - The company is looking for support to advance CTH-401 and expand its pipeline of off-the-shelf immune cell therapies.

The bottom line: - Cartherics is pairing a clinical milestone with a partnering push as it tries to move its ovarian cancer program from development into the clinic.